Original Article

Effects of Quercetin Supplementation on Oxidative Stress, Blood Pressure, Aerobic Power, Concentric Pathologic Hypertrophy and Cardiac Function in Men with Hypertension and Coronary Artery Disease After Percutaneous Coronary Intervention: a Randomized, Double-Blind Placebo-Controlled Trial

Khalil Ollah Moonikh1, Majid Kashef2, Khalil Mahmoudi3, Mojtaba Salehpour4

1- PhD student of Cardiovascular Exercise Physiology, Faculty of Physical Education and Sports Sciences, Shahid Rajaee Teacher Training University, Tehran, Iran.
2- Professor of Exercise Physiology, Sport Sciences Faculty, Shahid Rajaee Teacher Training University, Tehran, Iran.
3- Associate Professor of Cardiology, Department of Cardiology, Zanjan University of Medical Sciences, Zanjan, Iran.
4- Assistant Professor of Exercise Physiology, Sport Sciences Faculty, Shahid Rajaee Teacher Training University, Tehran, Iran.

Received: February 2020
Accepted: April 2020

ABSTRACT

Background and Objectives: The aim of this study was to investigate possible effects of quercetin supplementation on oxidative stress, blood pressure, aerobic power, concentric pathologic hypertrophy and cardiac function in men with hypertension and coronary artery disease (CAD) after percutaneous coronary intervention (PCI).

Materials and Methods: The present study was a randomized, double-blind clinical trial; in which, 24 men with hypertension and CAD after PCI (aged 40–60 years) were participated. Patients were prescribed quercetin (250 mg/day) or placebo for two months. Plasma total antioxidant capacity (TAC) and malondialdehyde (MDA) were assessed using colorimetric methods as well as left ventricular diastolic dysfunction (LVDD), p wave depression (PWD), ejection fraction (EF) and E/A using echocardiography and WRp using Storer-Davise cycle test. Systolic and diastolic blood pressures were measured before and after the intervention. Data were analyzed using ANCOVA and paired-sample T-test.

Results: Supplementation resulted in a significant improvement in oxidative stress reduction (TAC increased and MDA decreased), systolic and diastolic blood pressures, systolic (EF) and diastolic (E/A) functions and aerobic power, compared to pretest and placebo groups following eight weeks of treatment (p < 0.05). A small decrease in RWT was seen in quercetin group at the end of intervention with no statistical significance (p > 0.05). The RWT was not significantly different between the quercetin and placebo groups (p > 0.05).

Conclusions: Quercetin supplementation can improve oxidative stress, blood pressure, left ventricular function and aerobic power in men with hypertension and CAD after PCI. However, this includes no effects on concentric pathologic hypertrophy. Further studies are necessary to verify effects of quercetin supplementation on left ventricular hypertrophy in humans.

Keywords: Quercetin, Oxidative stress, concentric pathologic hypertrophy, Left ventricular function, blood pressure, CAD

Introduction

Cardiovascular disease (CVD) is the leading cause of mortality in world [1]. Coronary artery disease (CAD) or coronary heart disease (CHD) and hypertension are the most prevalent CVDs [1]. Risk factors of CAD (including hypertension) increase oxidative stress [2]. Oxidative stress occurs from an excessive production of ROS that surpasses the antioxidant system [3]. Oxidative stress that causes vascular inflammation initiates the first stage of CAD and leads to pro-atherogenic events such as LDL oxidation, endothelial dysfunction, proliferation and migration of the vascular smooth muscle cells and eventually coronary artery stenosis [2]. Angioplasty or percutaneous coronary intervention (PCI) is a method used to reopen obstructed coronary arteries caused by CADs [1]. Patients experiencing PCI...
typically need minimum preparation, improve within hours and can usually be discharged on the day of intervention [4]. Although procedural death associated with PCI is low (0.1%), many cases experience growing re-narrowing or sudden blockage of the stent [1]. Studies have shown that oxidative stress increases in patients after PCI [5, 6]. Coronary interventions, consisting of balloon angioplasty and coronary stent implantation, are correlated with enhanced vascular levels of reactive oxygen species (ROS) as well as altered endothelial cell and smooth muscle cell functions. Those alter-actions potentially cause thrombosis, restenosis or endothelial dysfunction in treated arteries [5]. Based on the previous studies, levels of oxidative stress and lipid peroxidation in patients with hypertension [7, 8] and coronary stenosis [2, 9–11] and patients after PCI [5, 6] are high and their antioxidant defense enzyme activity is relatively low. Generally, ROS cause CVDs, including hypertension, cardiac hypertrophy, atherosclerosis and heart failure [12]. Furthermore, oxidative stress negatively affects cardiac muscle function and exercise performance through molecular alterations in heart muscles [13] in these patients [7, 8, 14]. Therefore, use of antioxidant supplements with medications may be beneficial in these patients. Bioflavonoids are reported as important antioxidants. In fact, these molecules are phenolic compounds that naturally exist in fruits and vegetables [15]. Nowadays, the value of bioflavonoids in preventing chronic diseases such as CVDs and atherosclerosis is well addressed [1, 3, 15, 16]. Quercetin is one of the most famous bioflavonoids, which is more abundant, compared to other flavonoids [1, 3, 15].

Quercetin has shown antioxidant properties in several studies [3, 17, 18]. Moreover, this compound has shown useful effects on blood pressure in humans and animals [18, 19]. Quercetin is effective in decreasing cardiovascular risk through various approaches such as diminishing oxidative stress and limiting platelet adhesion [15, 16]. Due to antioxidant properties of quercetin and recommendations by pioneer researches to assess effects of this supplement in diseases with high oxidative conditions, use of quercetin is suggested in patients with hypertension and coronary stenosis and patients after PCI [17, 20]. Previous studies have shown that quercetin prescription of 1 g daily is well tolerated by humans [3, 15]. In numerous studies (humans and animals), quercetin supplementation has been reported safe with no adverse symptoms or harmful physiological effects [1, 3, 21, 22]. To the best of the authors’ knowledge, effects of quercetin on oxidative stress in patients post PCI has not been studied previously. Although a study has investigated effects of quercetin in patients with CAD, effects of quercetin on oxidative stress have not been investigated in these patients [16]. Therefore, the present study was carried out to investigate effects of quercetin on oxidative stress, blood pressure, aerobic power, concentric pathologic hypertrophy and cardiac function in men with hypertension and CAD after PCI.

Materials and Methods

Subjects: The present study was a randomized, double-blind clinical trial; in which, 24 men with hypertension and CAD after PCI were participated from Bahman Hospital Cardiac Rehabilitation Center, Zanjan, Iran, 2019. The minimum sample size per subgroup was ten during the empirical investigation. In this study, the smallest example size was selected due to the small number of available subjects (n = 60) based on the inclusion criteria. Another reason included difficulties in access to people with hypertension and CAD after PCI. Before commencing the study, written informed consents were received from the participants. Furthermore, study was approved by the Ethics Committee of Sport Sciences Research Institute of Iran and registered in Iranian Registry of Clinical Trials (registration no. IRCT20160927030023N3). Inclusion criteria for the participants were men, aged 40–60 year old, with hypertension (systolic blood pressure/diastolic blood pressure higher than 135/85 mm Hg), concentric myocardial hypertrophy [wall thickness to diastolic end dimension greater than 0.42 (RWT > 0.42)], EF above 30, PCI within the past month and approximately similar drug uses (unchanged types and doses of medications from the last month). The participants were excluded from the study if changing the highlighted criteria, having other diseases that might require special treatments, smoking, having acute illnesses and unwilling to continue the study. The participants continued their treatments during the intervention with the same type and dose of medications.

Design: Participants were categorized into two major groups of quercetin supplement and placebo groups using blocked randomization method. The supplement group used 250 mg/day of quercetin (Solaray, USA) and the placebo group used an identical placebo capsule containing lactose (Daroupakhsh, Iran) for eight weeks. Participants were advised not to change their diets and physical activities during the study. At the beginning of the intervention, participant characteristics, types and doses of medications and histories of past diseases were asked. Weight and height of the participants were measured using standard protocol with light clothes with no shoes to the nearest 0.5 kg and 0.5 cm and then body mass indices (BMI) were calculated. The body fat proportion was calculated using bioelectrical...
impedance analysis (X-Contact 356; Jawon Medical, Republic of Korea). Blood pressure was measured twice at sitting position and after 5–10 min using analog sphygmomanometer (Omron Random Zero Blood Pressure Analyzer, Japan) and the average of the two stages was recorded. Data of dietaries were collected using 24-h recall procedure within two days, including one normal day and one holiday. Two-day mean values of the energy and nutrient intakes of the participants were calculated using Nutritionist IV Software v.4.1 (First Databank Division, Hearst, USA).

Biochemical analysis: Before and after the intervention, venous blood samples were collected after at least 8–10 h of fasting. Blood plasmas were separated using 10 min of centrifuging at 2000 g and stored at -80 °C until biochemical analyses. During the intervention, participants were regularly monitored using phone calls. At the end of the study, compliance was assessed by counting the number of capsules. Participants who used less than 80 percent of quercetin and placebo capsules were excluded from the study. The TAC of plasma was measured using colorimetric method and antioxidant assay kit (Novin Salamat, Iran) with an assay range of 0.044–0.33 mmol/L according to the manufacturer’s instructions. Malondialdehyde (MDA) was assessed using colorimetric method and thiobarbituric acid reactive substances (TBARS) assay kit (Novin Salamat, Iran) with a dynamic range of 0–50 μmol/L for the colorimetric method at standard conditions according to the manufacturer’s instructions.

Echocardiography: All participants were subjected detailed echocardiographic analyses with images reviewed by an expert cardiologist. Echocardiography was carried out in primary care settings using portable VIVID I Machine (GE Healthcare, UK). The LV end-diastolic diameter (LVEDD), posterior wall thickness (PWT), LV ejection fraction and diastolic function parameter (E/A ratio of the mitral valve) were measured following current recommendations [23]. The relative wall thickness (RWT) was calculated as 2 × PWT / LVEDD (concentric hypertrophy if RWT was ≤ 0.42) [24].

\[ \text{RWT} = \frac{2 \times \text{posterior wall}}{\text{left ventricular diastolic diameter}} \]

**Peak work rate (WRp)/peak aerobic power measurement:** Each participant carried out a ramp-incremental exercise test, using Storer-Davise cycle test [25]. To carry out Storer-Davise cycle test, the participant initially pedaled with no resistance (0W) for a 4-min warmup. A constant pedaling cadence of 60 rev/min was programmed during the test. After the warmup, the work rate increased at 0.30 kP/min (15 W/min) until the participant was unable to generally continue or to continue on the constant pedaling cadence of 60 rev/min. The peak work rate (WRp) was calculated as the highest work rate (WR) reached and maintained at a pedaling frequency of no less than 60 rpm for 30 s. Supervisions by exercise physiologists, physicians and physical therapists were carried out during the exercise sessions and further included periodical blood pressure measurement, ECG continuous recording, Borg evaluation scale and peripheral oxygen saturation monitoring.

**Statistical methods:** All values were reported as mean ±SD (standard deviation). Kolmogorov-Smirnov test was used to check if distribution of the quantitative variables was normal. Independent t-test and analysis of covariance (ANCOVA) were used to compare between the two groups at the beginning and the end of the interventions, respectively. Paired t-test was used to compare the mean values before and after the interventions. The SPSS Statistical Software v.15 (IBM Analytics, USA) was used for data analysis. The level of \( p \leq 0.05 \) was considered statistically significant.

**Results**

totally, 24 participants (12 participants in each group) completed the study and then per-protocol statistical analyses were carried out. Independent t-test showed that weight, BMI, age, height and body fat proportion were not significantly different between the quercetin and placebo groups (Table 1).

The daily energy and nutrient intakes are shown in Table 2.

| Table 1. Baseline characteristics of the participants |
|-----------------------------------------------------|
| Variable | Quercetin group (n=12) | Placebo group (n=12) | \( P \) value† |
|----------|------------------------|---------------------|---------------|
| Age (years) | 57.18±4.25 | 56.23±4.38 | 0/65 |
| Height (cm) | 169.8±7.21 | 170.6±3.83 | 0/76 |
| Weight (kg) | 74.86±10.46 | 77.32±7.12 | 0/29 |
| BMI\(^{1}\) (kg/m2) | 25.96±3.58 | 26.56±2.16 | 0/44 |
| Body fat (percentage) | 23.95±5.79 | 23.42±2.78 | 0/78 |

Values are expressed as mean ±SD (standard deviation); \(^{1}\)BMI, body mass index; †independent t test
Table 2. Daily energy, macronutrient and micronutrient intakes in the two groups

|                      | Quercetin group \((n=12)\) | Placebo group \((n=12)\) | \(P\) value† |
|----------------------|----------------------------|---------------------------|--------------|
| Energy (kcal/d)      | 2081.4±224.2               | 2151.3±302.4              | 0.53         |
| Carbohydrate (g/d)   | 320.3±46.7                 | 335.5±53.4                | 0.48         |
| Protein (g/d)        | 81.6±41                    | 83.5±42                   | 0.55         |
| Lipid (g/d)          | 55.5±14                    | 53.6±16                   | 0.30         |
| Vitamin A (RAE/d)    | 724.2±421.9                | 708.2±621.10              | 0.49         |
| Vitamin E (mg/d)     | 2.97±0.2                   | 2.71±2.2                  | 0.78         |
| Vitamin C (mg/d)     | 76.8±14.88                 | 79.7±53.18                | 0.56         |
| Vitamin D (μg/d)     | 1.19±1.64                  | 1.09±1.20                 | 0.75         |
| Fe (mg/d)            | 13.08±3.95                 | 12.99±4.01                | 0.67         |
| Zn (mg/d)            | 6.62±4.32                  | 6.80±3.95                 | 0.85         |

Values are expressed as mean ±SD (standard deviation); †independent t test

As shown in Table 3, ANCOVA analysis and paired t test showed that quercetin supplementation significantly improved oxidative stress decreases (TAC increased and MDA decreased), systolic and diastolic blood pressures (both decreased), systolic (EF) and diastolic (E/A) functions (both increased) and aerobic power (increased significantly), compared to pretest and placebo groups following eight weeks of treatments (\(p < 0.05\)). A little decrease in RWT was seen in quercetin group at the end of intervention with no statistical significance (\(p > 0.05\)). The RWT values were not significantly different between the quercetin and placebo groups after eight weeks (\(p>0.05\)). Paired t test showed no statistically significant differences for the mean placebo group values (\(p > 0.05\)).

Table 3. Biochemical and echocardiographic parameters, aerobic power and blood pressure of the participants before and after eight weeks of supplementation

|                      | Quercetin group \((n=12)\) | Placebo group \((n=12)\) | \(P\) value† |
|----------------------|-----------------------------|---------------------------|--------------|
| TAC (mmol Fe⁺⁺/L)    | 0.91±0.27                   | 0.92±0.26                 | 0.938†       |
| Before               | 1.07±0.33                   | 0.94±0.21                 | 0.032†       |
| After                |                            |                           |              |
| \(P\) value³        | 0.028                       | 0.339                     |              |
| MDA (mmol/ml)        | 27.10±2.15                  | 28.85±5.46                | 0.574‡       |
| Before               | 23.40±5.2                   | 28.09±5.27                | 0.042‡       |
| After                |                            |                           |              |
| \(P\) value³        | 0.038                       | 0.341                     |              |
| Systolic blood pressure (mmHg) | 143.7±10.23              | 144.4±10.58               | 0.861‡       |
| Before               | 135.5±9.96                  | 143.2±10.25               | 0.002‡       |
| After                |                            |                           |              |
| \(P\) value³        | 0.002                       | 0.186                     |              |
| Diastolic blood pressure (mmHg) | 86.54±4.82                  | 87.55±4.80                | 0.632‡       |
| Before               | 80.09±5.00                  | 86.36±4.10                | 0.004‡       |
| After                |                            |                           |              |
| \(P\) value³        | 0.005                       | 0.351                     |              |
| LVPWd (mm)           | 47.45±2.39                  | 47.68±2.50                | 0.830‡       |
| Before               | 47.81±2.48                  | 47.60±2.74                | 0.890‡       |
| After                |                            |                           |              |
| \(P\) value³        | 0.340                       | 0.298                     |              |
| RWT (percentage)     | 51.00±5.21                  | 50.18±3.81                | 0.702‡       |
| Before               | 53.27±5.62                  | 50.50±4.41                | 0.032‡       |
| After                |                            |                           |              |
| \(P\) value³        | 0.030                       | 0.586                     |              |
| LVEF (percentage)    | 0.780±0.124                 | 0.767±0.88                | 0.782‡       |
| Before               | 0.812±0.127                 | 0.760±0.87                | 0.023‡       |
| After                |                            |                           |              |
| \(P\) value³        | 0.021                       | 0.314                     |              |
| WRp (watts)          | 98.18±26.29                 | 100.25±18.60              | 0.402‡       |
| Before               | 109.09±22.34                | 100.50±18.60              | 0.002‡       |
| After                |                            |                           |              |
| \(P\) value³        | 0.000                       | 0.166                     |              |

Values are expressed as mean ±SD (standard deviation); TAC, total antioxidant capacity; MDA, malondialdehyde; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVPWd, LV posterior wall thickness; LVEd, LV end diastolic diameter; RWT, relative wall thickness; LVEF, LV ejection fraction; E/A ratio, peak early filling (E wave) and late diastolic filling (A wave) velocity ratio; WRp, peak work rate; ³ANCOVA was used to compare differences between the two groups after eight weeks (adjusted for baseline values); †independent t test; ‡paired t test
Discussion

Based on the current knowledge, this study is the first study to investigate effects of quercetin supplementation (250 mg/day) on oxidative stress in patients with CAD. In this study, quercetin supplementation resulted in significant decreases in plasma levels of MDA as well as significant increases in plasma TAC. These results are similar to results from other studies such as those by Chiodo et al. [26], Monteiro et al. [36], Kandhare et al. [27], Kumar et al. [28], Duarte et al. [20], Galisteo et al. [29] and Boots et al. [17]; in which, ROS and MDA levels decreased and activities of antioxidant enzymes of SOD, CAT and TAC increased following supplementation with quercetin. A previous study by the authors showed similar results from six weeks of quercetin supplementation [3]. Of flavonoids, quercetin includes the strongest antioxidant characteristic due to the presence of OH group in B and C-rings [3]. Quercetin represses free radicals in three stages, including generation of hydroxyl radicals in Fenton reaction, formation of lipid peroxy radicals and formation of superoxide ions [30, 31]. In contrast, Cammerer et al. [32] showed that a flavonoid-based antioxidant-rich diet included no effects on oxidative stress, six months after PCI. Furthermore, Kammer et al. used a flavonoid-rich diet contrary to the pure quercetin used in the present study. In a study by Javadi et al. [15], quercetin did not affect plasma TAC and MDA levels in patients with RA. However, participants of the current study were different from those of Javadi's study, moreover, blood concentration of quercetin might be different. Various doses of 730 mg supplementation (for 28 days) in prehypertensive patients [33], 150 mg per day (for two weeks) in obese patients with metabolic syndrome [19] and 1000 mg per day (for three weeks) in athletes after sports matches [34] showed no significant effects on antioxidant capacity of the plasma. Duration of the intervention in these studies was much less than that in the present study.

In the present study, a significant effect was reported on blood pressure, which was similar to that reported by Egert et al. [19]. Egert et al. [19] found that quercetin led to a significant decrease in systolic blood pressure of all participants with obesity and hypertension. Whereas, Edwards et al. [33] reported that quercetin included no significant effects on blood pressure in pre-hypertensive patients. Only patients in Stage 1 of hypertension showed significant decreases in systolic and diastolic blood pressures. In the current study, quercetin showed an effect on blood pressure, possibly because patients suffered from hypertension. Researchers have investigated antihypertensive effects of quercetin in animal models of essential hypertension. Quercetin in hypertensive rats decreased blood pressure. In contrast, quercetin did not affect normotensive rats. Additionally, quercetin decreased cardiac hypertrophy. These effects were associated with a decreased oxidant status due to the antioxidant properties of quercetin [20]. In another study, quercetin (0.1 g/kg) demonstrated both antihypertensive and antioxidant properties in hypertensive rat models. Quercetin also inhibited cardiac hypertrophy [29]. In a study by Garcia-Saura et al., quercetin supplementation decreased systolic blood pressure of Goldblatt hypertensive rats [35]. The compound decreased cardiac hypertrophy developed in Goldblatt hypertensive rats. In the current study, eight weeks of quercetin supplementation significantly improved left ventricular systolic (EF) and diastolic (E/A) functions. In contrast, quercetin showed no significant effects on concentric pathologic hypertrophy (RWT). Up to date, only two studies have investigated effects of quercetin on structure and function of the heart in humans [16, 36]. Results of these two studies are similar to results of the present study. Effects of quercetin on oxidative stress in these studies have not been investigated. In the current study, quercetin increased LV systolic and diastolic functions by decreasing oxidative stress and increasing antioxidant defense system. In a study of Castillo et al. [37], quercetin prevented cardiac diastolic dysfunction in the same blood vein. Furthermore, quercetin decreased oxidative stress. Therefore, mechanisms that support cardioprotective effects of quercetin might be mediated by the upregulation of antioxidant mechanisms on the heart. In human studies, quercetin included no significant effects on heart structure and hypertrophy [16, 36]. In the present study, a little decrease in RWT was seen in quercetin group at the end of the intervention with no significance. Whereas, quercetin supplementation decreased cardiac hypertrophy induced by pressure overload in rats [20, 28, 29, 38–40]. In these animal studies, daily quercetin doses were much more than those in the current study.

Findings of this study have suggested that eight-week supplementation with quercetin improves the endurance performance. This has been shown in several studies [3, 21, 41–44]. It is possible that quercetin improves mitochondrial biogenesis in humans; therefore, improves aerobic capacity [21, 45]. Furthermore, decrease of oxidative stress and improvement of heart function can be the mechanism; through which, quercetin develops aerobic capacity [3, 45]. For the first time in this study, dietary supplementation with quercetin (250 mg daily for 56 days) increased endurance capacity in men with heart diseases. However, findings were not similar to those
reported by some other researchers [46, 47]. Ganio et al. showed that five days of quercetin supplementation did not increase aerobic capacity in untrained individuals [47]. Cureton et al. found that 1 g/day of quercetin supplementation (7–16 days) included no significant effects on VO2 peak and perception of efforts or metabolic responses during submaximal cycling [46]. Period of quercetin supplementation in this study (eight weeks) was much longer than that in Ganio et al. study (five days) and Cureton et al. (9–16 days). Although this study was the first randomized, double-blind placebo-controlled trial to assess effects of quercetin on oxidative stress, blood pressure, aerobic power, concentric pathologic hypertrophy in patients with hypertension and CAD after PCI, it included limitations. These limitations included the short-term intervention period and the little sample size. Lack plasma quercetin measurement due to the lack of laboratory capacity was another limitation. Similarly, information bias that might occur due to the self-reported dietary intake was a limitation within this study.

CONCLUSIONS

In general, this study showed that quercetin supplementation improved oxidative stress indices, blood pressure, aerobic power and cardiac function in men with hypertension and CAD after PCI. However, quercetin did not affect levels of concentric pathologic hypertrophy (a little decrease in RWT was seen with no significance). Greater sample sizes, longer intervention periods and higher doses of quercetin are suggested in future studies to establish the effectiveness of quercetin on levels of concentric pathologic hypertrophy.

Acknowledgement

The authors sincerely thank volunteers for their participation in the study. This study was financially supported by Shahid Rajaee Teacher Training University.

Financial disclosure

No conflicts of interest are reported.

References

1. Kashef M, Mahmoudi K, Salehpour M, Moonikh K. The effect of high-intensity interval training (HIIT) and quercetin supplementation on dimension and functional left ventricular adaptations in men with hypertension and CAD after PCI. Daneshvar Medicine. 2019; 27 (5) :35-48.

2. Suen J, Thomas J, Kranz A, Vun S, Miller M. Effect of Flavonoids on Oxidative Stress and Inflammation in Adults at Risk of Cardiovascular Disease: A Systematic Review. Healthcare (Basel). 2016 Sep 14; 4(3). pii: E69. doi: 10.3390/healthcare4030069

3. Ramezani A, Moonikh K. Effect of Quercetin Supplementation on Oxidative Stress and Exhaustion in Male Soccer Players. J. Med. Plants. 2017; 2 (62) :136-144.

4. Lauck S, Jonson J, Partner P. Self care behaviour and factors associated with patient outcomes following same day discharge percutaneous coronary intervention. European journal of cardiovascular nursing, 2009; 8, 190-199.

5. Juni RP, Duckers HJ, Vanhoutte PM, Virmani R, Moens AL. Oxidative Stress and Pathological Changes After Coronary Artery Interventions. Journal of the American College of Cardiology. 2013; 61(14): 1472-81.

6. Leibundgut G, Lee JH, Segev A, Strauss BH and Tsimikas S. Acute and Long-Term Effect of Percutaneous Coronary Intervention on Serially-Measured Oxidative, Inflammatory, and Coagulation Biomarkers in Patients with Stable Angina. J Thromb Thrombolysis. 2016; 41(4): 569–580. doi:10.1007/s11239-016-1351-6.

7. Farzanegi P, Habibian M, Kaftari A. Effect of 6-weeks aerobic exercise training on oxidative stress and enzymatic antioxidants in postmenopausal women with hypertension: Case Study. J Mazandaran Univ Med Sci. 2014; 23(108) :134-136. [Article in Persian]

8. Bowen TS, Eisenkolb S, Drobnar J, Fischer T, Werner S, Linke A. High-intensity interval training prevents oxidant-mediated diaphragm muscle weakness in hypertensive mice. FASEB J. 2017 ;31(1):60-71. doi: 10.1096/fj.201600672R. Epub 2016 Sep 20.

9. Weinbrenner T, Cladellas M, Covas MI, et al. High oxidative stress in patients with stable coronary heart disease. Atherosclerosis. 2003; 168(1): 99-106.

10. Azarsiz E, Kayikcioglu M, Payzin S, Yildirim Sozmen E. PON1 activities and oxidative markers of LDL in patients with angiographically proven coronary artery disease. Inter J Cardiol. 2003; 91: 43-51.

11. Serdar Z, Aslan K, Dirican M, Sarandol E, Yesilbursa D, Serdar A. Lipid and protein oxidation and antioxidant status in patients with angiographically proven coronary artery disease. Clin Biochem. 2006; 39: 794-803.

12. Jain AK, Mehra NK, Swarnakar NK. Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities. Curr Pharm Des. 2015; 21(30):4441-55.

13. Baghaiee B, Siaikhouhian M, Karimi P and Teixeira M. Weight Gain and Oxidative Stress in Midlife Lead to Pathological Concentric Cardiac Hypertrophy in Sedentary Rats. Journal of Clinical Research in Paramedical Sciences. 2018; Vol 6, No 3, 1-7.

14. Ranbar K, Nazem F, Nazari A. Effect of Exercise Training and L-arginine on Oxidative Stress and Left Ventricular Function in the Post-ischemic Failing Rat...
Heart. Cardiovasc Toxicol. 2016 Apr;16(2): 122-9. doi: 10.1007/s12012-015-9319-x.

15. Javadi F, Eghtesadi S, Ahmadzadeh A, Aryaeian N, Zabihiyeganeh M, Foroushani AR, et al. The effect of quercetin on plasma oxidative status, C-reactive protein and blood pressure in women with rheumatoid arthritis. Int J Prev Med 2014;5:293-301.

16. Chekalina NI, Shut SV, Trybrat TA, Burmak YH, Petrov YY, Manusha YI, Kazakov YM. Effect of quercetin on parameters of central hemodynamics and myocardial ischemia in patients with stable coronary disease. Wiadomosci lekarskie. 2017; 70(4):707-711.

17. Boots AW, Drent M, de Boer VC, Bast A, Haenen GR. Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clin Nutr. 2011 Aug;30(4):506-12. doi: 10.1016/j.clnu.2011.01.010. Epub 2011 Feb 15.

18. Monteiro MM, Franca-Silva MS, Alves NF, Poprino SK, Braga VA. Quercetin improves baroreflex sensitivity in spontaneously hypertensive rats. Molecules. 2012 Nov 1;17(11):12997-3008. doi: 10.3390/molecules171112997.

19. Egert, S, Bosy-Westphal, A, Seiberl, J, Kürbitz, C, Settler, U, Plachta-Danielzik, S. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: A double-blinded, placebo-controlled cross-over study. Br J Nutr. 2009; 102(7): 1065-74.

20. Duarte J, Pérez-Palencia R, Vargas F, et al. Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. Br J Pharmacol. 2001;133:117-24.

21. Davis JM, Carlstedt CJ, Chen S, Carmichael MD, Murphy EA. The dietary flavonoid quercetin increases VO (2 max) and endurance capacity. Int J Sport Nutr Exerc Metab 2010;20:56-62.

22. Knab A. M, Shanely R. A, Henson D. A, et al. Influence of quercetin supplementation on disease risk factors in community-dwelling adults. J Am Diet Assoc. 2011;111(4):542-9.

23. Lang RM, Bierig M, Devereux RB, Flachskaempf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. European journal of echocardiography: the journal of the Working Group on Echocardiography of the European Society of Cardiology. 2006;7(2):79–108.

24. Zare Karizk S, Kashef M, Gacini AA, Nejatian M. The Comparison of Two Protocol of Interval and Continues Aerobic Training on Level of Concentric Pathologic Hypertrophy and Cardiac Function in Patients after Coronary Artery Bypass Grafting surgery. Journal of Practical Studies of Biosciences in Sport 2016; 5(9): 9-20.

25. Storer TW, Davis JA, and Caozzo VI. Accurate prediction of Vo2max in cycle ergometry. Med Sci Sport Exerc 1990; 22: 704-712.

26. Chiodo SG, Leopoldini M, Russo N, Toscano M. The inactivation of lipid peroxide radical by quercetin. A theoretical insight. Phys Chem Chem Phys. 2010 Jul 21;12(27):7662-70.

27. Kandhare AD, Raygude KS, Shiva Kumar V, Rajmane AR, Visnagri A, Ghule AE, et al. Ameliorative effects quercetin against impaired motor nerve function, inflammatory mediators and apoptosis in neonatal streptozotocin-induced diabetic neuropathy in rats. Biomedicine & Aging Pathology. 2012; 2(4): 173-186.

28. Kumar M, Kasala ER, Bodduluru LN, Kumar V, Lahkar M. Molecular and biochemical evidence on the protective effects of quercetin in isoproterenol-induced acentumyocardial injury in rats. J Biochem Mol Toxicol. 2017; 31(1):1-8. doi: 10.1002/jbt.21832. Epub 2016 Aug 15.

29. Galisteo M, Garcia-Saura MF, Jimenez R, Villar IC, Vangensteen R, Zarzuelo A, et al. Effects of chronic quercetin treatment on antioxidant defense system and oxidative status of deoxycorticosterone acetate-salt hypertensive rats. Mol Cell Biochem. 2004; 259(1-2): 9-91.

30. Sim GS, Lee BC, Cho HS, et al. Structure activity relationship of antioxidative property of flavonoids and inhibitory effect on matrix metalloproteinase in UVA-irradiated human dermal fibroblast. Arch Pharm Res. 2007 Mar;30(3):290-8.

31. da Silva EL, Abdalla DS and Terao J. Inhibitory effect of flavonoids on low-density lipoprotein peroxidation catalyzed by mammalian 15-lipoxygenase. IUBMB life. 2000;49(4):289-95.

32. Cammerer MA, Gonçalves SC, de Araujo GN, Andrades ME, Lopes A, Wainstein MV. The Effects of a Flavonoid-Rich Diet on Oxidative Stress, Inflammation, and Lipid Profile after Elective Percutaneous Coronary Intervention: A Randomized Clinical Trial. Prev Nutr Food Sci. 2018; 23(2):108-114. doi: 10.3746/pnfs.2018.23.2.108. Epub 2018 Jun 30.

33. Edwards, RL, Lyon, T, Litwin, SE. Rabovsky, A, Symons, JD, Jalili, T. Quercetin reduces blood pressure in hypertensive subjects. J Nutr 2007 137:2405–11.

34. Quindry JC, McAnuity SR, Hudson MB, Hosick P, Dumke C, McAnuity LS, et al. Oral quercetin supplementation and blood oxidative in response to ultramarathon competition. Int J Sport Nutr Exerc Metab. 2008; 18(6): 601-16.

35. Garcia-Saura MF, Galisteo M, Villar IC, et al. Effects of chronic quercetin treatment in experimental renovascular hypertension. Mol Cell Biochem. 2005 Feb;270(1-2):147-55.

36. Kondratuij VE, Synistsia YP. Effect of quercetin on the echocardiographic parameters of left ventricular
diastolic function in patients with gout and essential hypertension. Wiadomosci lekarstw. 2018; 71(8):1554-1559.

37. Castillo RL, Herrera EA, Gonzalez-Candia A, Reyes-Farias M, Jara ND, Peña JP, Carrasco-Pozo C. Quercetin Prevents Diastolic Dysfunction Induced by a High-Cholesterol Diet: Role of Oxidative Stress and Bioenergetics in Hyperglycemic Rats. Hindawi Oxidative Medicine and Cellular Longevity, 2018; 1(1):1-14. doi.org/10.1155/2018/7239123

38. Han JJ, Hao J, Kim CH, Hong JS, Ahn HY, Lee YS. Quercetin prevents cardiac hypertrophy induced by pressure overload in rats. J Vet Med Sci. 2009 Jun;71(6):737-43.

39. Yan L, Zhang JD, Wang B, Lv YJ, Jiang H, et al. Quercetin Inhibits Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats and Inhibits Angiotensin II-Induced H9C2 Cells Hypertrophy by Enhancing PPAR-ε Expression and Suppressing AP-1 Activity. PLoS ONE. 2013; 8(9):1-14.

40. Ulasova E, Perez J, Bradford G. Hill, Wayne E. Bradley, David W. Garber, Aimee Landar. Quercetin prevents left ventricular hypertrophy in the ApoE knockout mouse. Redox Biol. 2013; 1(1): 381–386.

41. Sriraksa N, Wattanathorn J, Muchimapura S, Tiamkao S, Brown K, Chaisiwamongkol K. Cognitive-enhancing effect of quercetin in a rat model of Parkinson's disease induced by 6-hydroxydopamine. Evid Based Complement Alternat Med. 2012; 2012: 823206.

42. Zhao L, Wu J, Yang J, Wei J, Gao W, Guo C. Dietary quercetin supplementation increases serum antioxidant capacity and alters hepatic gene expression profile in rats. Exp Biol Med (Maywood). 2011; 236(6): 701-6.

43. Lin Y, Liu HL, Fang J, Yu CH, Xiong YK, Yuan K. Anti-fatigue and vasoprotective effects of quercetin-3-O-gentiobiose on oxidative stress and vascular endothelial dysfunction induced by endurance swimming in rats. Food Chem Toxicol. 2014; 68:290-6. doi: 10.1016/j.fct.2014.03.026. Epub 2014 Mar 29.

44. Dumke CL, Nieman DC, Utter AC, Rigby MD, Quindry JC, Triplett NT, et al. Quercetin's effect on cycling efficiency and substrate utilization. Appl Physiol Nutr Metab 2009; 34(6): 993-1000.

45. Scholten SD, Sergeev IN. Long-term quercetin supplementation reduces lipid peroxidation but does not improve performance in endurance runners. Open Access J Sports Med. 2013;4:53–61.

46. Cureton KJ, Tomporowski PD, Singhal A, Pasley JD, Bigelman KA, Lambourne K, et al. Dietary quercetin supplementation is not ergogenic in untrained men. J Appl Physiol 2009;107:1095-104.

47. Ganio MS, Armstrong LE, Johnson EC, Klau JF, Ballard KD, Michniak-Kohn B, et al. Effect of quercetin supplementation on maximal oxygen uptake in men and women. J Sports Sci 2010;28:201-8.